Drugs / QBS72S
Trials 1
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 2 | NCT05305365 | Aug 2022 → Jun 2025 overdue | breast cancer, lung cancer, metastatic malignant neoplasm in the brain, neoplastic meningitis | Stanford University | Active not recruiting | No outcome recorded |
Press releases naming this drug 3 releases
| Date | Issuer | Release |
|---|---|---|
| 2023-04-11 | Quadriga Biosciences, Inc. | Quadriga BioSciences Announces Dosing of First Subject in Phase 2 Study Evaluating QBS72S For Brain Metastases of Breast Cancer quadrigabiosciences.com ↗ |
| 2023-02-14 | Quadriga Biosciences, Inc. | Quadriga BioSciences Announces Dosing of First Subject in Phase 2 Study Evaluating QBS72S For Glioblastoma quadrigabiosciences.com ↗ |
| 2022-10-25 | Quadriga Biosciences, Inc. | Quadriga BioSciences Announces Completion of Enrollment in Phase 1 Study of QBS72S for Solid Tumors quadrigabiosciences.com ↗ |
Evidence & citations 2 cited values
Every value below carries the sentence it was read from. 1 source stands behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | QBS72S | ClinicalTrials.gov intervention name — accepted as the source's own label NCT05305365 ↗ |
| Route | Intravenous | “QBS72S 18mg/m2 injection given intravenous once a month.” NCT05305365 ↗ |